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Background: Rab proteins constitute a large family of monomeric GTP-binding proteins that regulate intracellular
vesicle transport. Several Rab proteins, including rab31, have been shown to affect cancer progression and are
related with prognosis in various types of cancer including breast cancer. Recently, the gene encoding rab31 was
found to be overexpressed in estrogen receptor-positive breast cancer tissue. In a previous study we found a
significant association of high rab31 mRNA expression with poor prognosis in node-negative breast cancer patients.
In the present study, we aimed to investigate the impact of rab31 (over)-expression on important aspects of tumor
progression in vitro and in vivo.
Methods: Breast cancer cells displaying low (MDA-MB-231) or no (CAMA-1) endogenous rab31 expression were
stably transfected with a rab31 expression plasmid. Batch-transfected cells as well as selected cell clones, expressing
different levels of rab31 protein, were analyzed with regard to proliferation, cell adhesion, the invasive capacity of
tumor cells, and in vivo in a xenograft tumor model. Polyclonal antibodies directed to recombinantly expressed
rab31 were generated and protein expression analyzed by immunohistochemistry, Western blot analysis, and a
newly developed sensitive ELISA.
Results: Elevated rab31 protein levels were associated with enhanced proliferation of breast cancer cells.
Interestingly, weak to moderate overexpression of rab31 in cell lines with no detectable endogenous rab31
expression was already sufficient to elicit distinct effects on cell proliferation. By contrast, increased expression of
rab31 in breast cancer cells led to reduced adhesion towards several extracellular matrix proteins and decreased
invasive capacity through MatrigelTM. Again, the rab31-mediated effects on cell adhesion and invasion were
dose-dependent. Finally, in a xenograft mouse model, we observed a significantly impaired metastatic
dissemination of rab31 overexpressing MDA-MB-231 breast cancer cells to the lung.
Conclusions: Overexpression of rab31 in breast cancer cells leads to a switch from an invasive to a proliferative
phenotype as indicated by an increased cell proliferation, reduced adhesion and invasion in vitro, and a reduced
capacity to form lung metastases in vivo.
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Compartmentalization of eukaryotic cells requires trans-
port of lipids and proteins between distinct membrane-
bound organelles. Rab GTPases, which belong to the Ras
superfamily of small GTP-binding proteins, are key regu-
lators of membrane trafficking in eukaryotic cells. Up to
now, more than 60 different human Rab proteins have
been identified [1,2]. The functions of Rab GTPases
depend on their ability to alternate between two conform-
ational states, the inactive (GDP-bound) and the active
(GTP-bound) state. Furthermore, their function depends
on their capacity to reversibly associate with specific
membrane compartments [3,4].
A growing number of Rab and Rab-related proteins has
been functionally characterized [for a review see 1].
Rab31, also known as rab22B, is a 194 amino acid protein
(Mr= 22,000), which shares highest homology with rab22A
(71% sequence identity). Rab31 is mainly localized to the
trans-Golgi, the trans-Golgi network (TGN) and to endo-
somes [4,5] and is involved in the vesicle transport from
the Golgi apparatus to early and late endosomes, e.g. of
mannose-phosphate receptors [6]. Furthermore, rab31 was
shown to modulate epidermal growth factor receptor
(EGFR) internalization in the epidermoid carcinoma cell
line A431 [7]. Interaction with GDP/GTP exchange factors
(GEFs) such as Gapex-5, EEA-1, and RIN proteins was
demonstrated [8,9]. Additionally, direct interaction with
the mRNA-binding protein HuR [10] and the phosphatidyl-
inositol(PI)-4,5-diphosphate-5-phosphatase ORCL-1 [11]
was observed. ORCL-1 plays a key role in the regulation of
the levels of PI(4)P and PI(4,5)P2, two signaling mole-
cules involved in membrane trafficking and Golgi/TGN
organization [11].
Dysfunctions in Rab pathways can lead to immunodefi-
ciencies and neurological disorders. Also, dysregulation
of Rab expression was shown to affect cancer progression
[12,13]. Rab31 was identified as one out of 11 genes that are
overexpressed in estrogen receptor (ER)-positive breast can-
cer patients [14]. Recently, we could show, that elevated
rab31 mRNA levels are significantly associated with shorter
distant metastasis-free and overall survival of untreated,
lymph node-negative breast cancer patients [15]. More
extensively characterized Rab proteins such as rab25 and
rab21 were shown to be associated with increase in tumor
cell proliferation and are required to promote cancer cell in-
vasion [13,16]. High expression levels of rab25 are present
in breast and ovarian cancer tissues and are associated with
poor outcome of the patients [17]. Conversely, rab25 over-
expression in cancer cell lines substantially suppressed cell
invasion in vitro and tumor formation in vivo [18]. This
indicates that dysregulation of Rab expression may exert
either tumorigenic or tumor suppressive effects [12].
However, little is known about the tumor biological
effects of rab31 expression in breast cancer. Therefore,in the present study we aimed at analyzing the impact of
differential rab31 expression in breast cancer cells on im-
portant aspects of tumor progression in vitro and in vivo.
Using proliferation, adhesion, and invasion assays, we first
characterized the phenotype of the cell transfectants with
different rab31 expression levels in vitro, and then moni-
tored the impact of rab31 expression on experimental
metastasis in a xenograft tumor model in mice. Increased
rab31 protein levels were associated with enhanced prolif-
eration of breast cancer cells, led to a reduced adhesion of
cells towards extracellular matrix proteins and decreased
invasive capacity through MatrigelTM. In addition, we
observed a significantly impaired metastatic dissemination
of rab31 overexpressing MDA-MB-231 cells to the lung
using a xenograft mouse model. Taken together, our results
demonstrate that rab31 overexpression leads to a switch
from an invasive to a proliferative phenotype as indicated
by an increased cell proliferation, reduced cell adhesion,
and decreased cellular invasion in vitro and in vivo.
Results
Generation and characterization of polyclonal antibodies
directed to rab31
For immunization of rabbits and chickens, purified human
rab31 carrying an N-terminal histidine (His)6-tag was used
and the generated polyclonal antibodies directed to rab31
(two derived from chicken, and four from rabbits) subse-
quently tested for specificity. The reaction pattern of the
IgG-fraction of the most suitable antibody from rabbit #3,
pAb RT3-IgG, by ‘one-sided ELISA’ [19] and Western blot
is depicted in Figure 1A and B. Using the ‘one-sided
ELISA’ assay, in which microtiter plates were coated with
rab31 antigen or unrelated control protein, we found a
strong reaction of pAb RT3-IgG with its immunogen
rab31-His as well as with recombinant GST-rab31 (which
consists of human rab31 fused C-terminally to the bacter-
ial glutathione S-transferase). No reaction was observed
when wells were coated with the control protein BSA in-
stead of rab31 (Figure 1A). Next, we analyzed whether
pAb RT3-IgG may cross-react with other members of the
Rab protein family that are closely related to rab31 such as
rab5 and rab22A. With exception of the C-terminal part
( 30 amino acids), which harbors important residues for
the interaction with Rab-binding proteins involved in
C-terminal prenylation [20], rab5 and rab22A are highly
homologous to rab31: within the N-terminal 167 residues,
rab31 shares 85 identical plus 60 homologous amino acids
with rab5 (=86.8% homology), and even 133 identical plus
20 homologous amino acids with rab22A (= 91.6% hom-
ology). To test for cross-reactions, equal amounts of re-
combinant human rab5, rab22A, and rab31 protein were
applied in Western blot analysis. Here, for rab5 no cross-
reaction was observed; for rab22A, a slight reaction was



























Figure 1 Characterization of polyclonal antibodies directed to human rab31. (A) The reaction pattern of polyclonal antibody (pAb) RT3-IgG
(black) and of the pre-immune rabbit serum (gray) was analyzed by a ‘one-sided ELISA’ assay [19]. rab31-His, purified recombinant, histidine-
tagged rab31, used for immunization; GST-rab31, purified recombinant GST-rab31 fusion protein; BSA, bovine serum albumin. (B) In Western blot
analyses, pAb RT3-IgG strongly reacts with recombinant rab31 and not at all or only weakly with the highly homologous Rab proteins rab5 and
rab22A, respectively. (C) Immunohistochemical staining of paraffin-embedded, formalin-fixed breast cancer specimens with pAb RT4-IgG. Specific
immunostaining is observed in the cytoplasm as well as in the nucleus of cancer cells (upper panel, see arrow), stromal cells are stained less
frequently (lower panel, see arrow).
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lyses of breast cancer tissue sections, both pAb RT3-IgG
and pAb RT4-IgG (from animal #4) were qualified for de-
tection of rab31. As depicted in Figure 1C, rab31immunostaining was mainly observed in the cytoplasm of
tumor cells with occasional perinuclear/nuclear staining.
Less frequently, elongated fibroblast-like cells within the
stroma were stained.
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overexpressing rab31
First, various breast cancer cell lines were analyzed by
quantitative PCR for endogenous rab31 mRNA expression
levels [15,21]. Highest rab31 mRNA expression was found
in ZR75 cells (ratio 33.4 zmol rab31 mRNA per zmol
TATA box-binding protein [TBP] mRNA, which was used
as a housekeeping gene for normalization). MDA-MB-231
and adriamycin-resistant MCF-7 cells expressed moderate
rab31 mRNA levels (ratio 20.2 and 24.0 rab31/TBP,
respectively), whereas MDA-MB-435 and CAMA-1 cells
did not express any detectable rab31 mRNA. Therefore,
for further experiments, we selected MDA-MB-231 cells
displaying a basal endogenous rab31 expression and the
two rab31-negative cell lines.
The expression pattern of rab31 in breast cancer cell
lines MDA-MB-231, CAMA-1, and MDA-MB-435 upon
stable transfection with the eukaryotic expression plasmid
pRcRSV harboring the rab31 cDNA sequence was initially
analyzed by Western blot analysis. In all cell lines tested,
















































Figure 2 Rab31 expression levels in stably transfected breast cancer
transfected MDA-MB-231 and CAMA-1 breast cancer cells in Western blot ana
transfected with the empty vector pRcRSV; batch, parental MDA-MB-231 (low
expression) cells were stably transfected with the pRcRSV-based rab31 express
MDA-MB-231 or CAMA-1 cells with differing high, medium or low protein leve
transfected MDA-MB-231 and CAMA-1 cells, determined by rab31-ELISA. Mean(apparent molecular weight of about 22 kDa; Figure 2A).
MDA-MB-231 cells transfected with the empty expression
vector pRcRSV (vector control) - in line with the PCR
results - displayed basal endogenous rab31 protein expres-
sion whereas CAMA-1 (and MDA-MB-435; data not
shown) vector control cells did not display any reactive
protein (Figure 2A). In addition, in the case of MDA-MB-
231 and CAMA-1 cells, cell clones were isolated from the
batch transfectants by two rounds of subcloning in order
to get individual cell lines expressing homogenous high,
medium or low levels of rab31 protein (Figure 2A).
In addition to Western blot analysis, rab31 protein levels
in cell lysates were quantified by our own rab31-specific
ELISA, employing the commercial mAb M01 (Novus Biolo-
gicals) as catcher antibody and pAb RT3-IgG for detection.
Rab31 protein values determined in cell lysates of MDA-
MB-231 and CAMA-1 vector control and batch cells, and
in isolated cell clones were very similar to the expression
levels monitored by Western blot analysis: highest rab31
antigen values were observed in the rab31 high expressing































cells. (A) pAb RT3-IgG specifically detects rab31 in cell lysates from stably
lyses. Vector control, MDA-MB-231, or CAMA-1 cells were stably
endogenous rab31 expression) or CAMA-1 (no endogenous rab31
ion vector; high, medium or low, selected cell clones of batch-transfected
ls of rab31. (B) Rab31 antigen values (ng/mg of total protein) in rab31-
values (± SEM) of at least three independent experiments are depicted.
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antigen was found in low expressing clones (0.46 ng/mg,
and <0.10 ng/mg protein, respectively; Figure 2B).
Transfected cells were also characterized by immunocy-
tofluorescence [22]. The intensity of rab31 immunocytos-
taining of transfected cells was in parallel with the results
obtained by Western blot analysis (data not shown).
Proliferative characteristics of breast cancer cells
overexpressing rab31
The impact of rab31 overexpression on tumor cell pro-
liferation was analyzed by manual cell enumeration.
MDA-MB-231 batch-transfected cells and single MDA-
MB-231 cell clones with low or medium rab31 expres-
sion showed no significant differences in cell growthA
MDA-MB-231 (low endogenous ra

































































Figure 3 Rab31 overexpression enhances proliferation of breast canc
detached with 0.05% EDTA-solution after 24, 48, 72 and 96 h of cultivation
Cell number at 24 h was set to 100%; increase in cell number was expresse
independent experiments are depicted. Statistically significant differences (
Only MDA-MB-231 cell clones with a homogenous high rab31 expression s
control cells. (B) CAMA-1 batch-transfected cells, as well as CAMA-1 cell clo
respectively, display a significant increase in cell proliferation compared torate. Only cells highly overexpressing rab31 (approxi-
mately 5-fold higher than basal endogenous rab31 levels
in the vector control cell line; see Figure 2B) showed
significantly enhanced cell proliferation after 72 and
96 h of culturing (p < 0.05; Figure 3A). To exclude clonal
effects, we analyzed various cell clones with either high,
medium or low rab31 expression levels to confirm that
cell clones with similar protein levels of rab31 behave
similarly with respect to cell growth (data not shown).
A comparable effect of rab31 overexpression on cell
growth was monitored in CAMA-1 cells. In contrast to
MDA-MB-231 cells, in transfected CAMA-1 cells (par-
ental CAMA-1 cells do not endogenously express rab31)
already low protein levels of rab31 seem to enhance cell














er cells in vitro. Cells were seeded in triplicate onto 24-well plates,
and counted with a Neubauer-chamber under trypan blue exclusion.
d relative to the 24 h value in %. Mean values (± SEM) of at least three
p < 0.05) to the vector control group are indicated by an asterisk. (A)
how a significant increase in cell proliferation compared to vector
nes with homogenous medium and high expression of rab31,
vector control cells after 96 h of cultivation.
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overexpression of rab31, as well as medium and high
expressing CAMA-1 cell clones were characterized by
significantly enhanced proliferation 96 h after cell plat-
ing (Figure 3B). Analysis of additional, individual cell
clones expressing high, medium, or low rab31 protein
levels again confirmed similar growth rates of cell clones
with similar levels of rab31 (data not shown). In FACS
analyses by employing annexin V staining, we found no
indication for any differences in apoptosis between vector
control and rab31 high overexpressing cells, neither in
MDA-MB-231 nor in CAMA-1 cells (data not shown).
Additionally, the human MDA-MB-435 cell line was
stably transfected with the rab31 expression plasmid.
Whether this cell line is derived from breast cancer or
from melanoma has been discussed controversial. Recent
results, however, indicate that this cell line should be
considered as a poorly differentiated, aggressive breast
tumor cell line, with expression of both epithelial and
melanocytic markers [23]. Alike CAMA-1 cells, parental
MDA-MB-435 cells do not endogenously express rab31.
Similarly, we observed that proliferation of MDA-MB-






























Figure 4 Rab31 overexpression reduces the adhesive capacity
of human breast cancer cells in vitro. Stably transfected MDA-MB-
231 cells (A) and CAMA-1 cells (B) were seeded on collagen type IV-
coated microtiter plates. After 2 h of cell cultivation, the number of
adherent cells was monitored by the hexosaminidase activity assay.
At least 5 independent experiments were performed in triplicates
each. The results are given in % relative to the cell number of
adherent vector-transfected control cells. Whisker box plots indicate
the 25th and 75th percentile, the vertical bars indicate the 10th and
90th percentile. The median value of at least 5 experiments is
indicated by a bar within the box. Statistically significant differences
(p < 0.05) to the vector control group are indicated by an asterisk,
differences between other groups are indicated by a line with an
asterisk.Adhesion of breast cancer cells to extracellular matrix
proteins
In order to analyze the effect of rab31 overexpression on
tumor cell adhesion, rab31-transfected breast cancer
cells were incubated on polystyrene plates coated with
different extracellular matrix (ECM) proteins. Towards
collagen type IV (Figure 4A), batch-transfected MDA-
MB-231 cells overexpressing rab31 showed moderate
but significantly reduced adhesion (reduction of 17.7%,
p < 0.05). When analyzing individual MDA-MB-231 cell
clones, we observed the strongest decrease of cellular
adhesion in rab31 high expressing cells (reduction of
28.0%, p < 0.05). For cells with medium rab31 expression,
a moderate reduction (17.6%, p < 0.05) in adhesive cap-
acity was observed. Low rab31 expressing cells dis-
played less pronounced but still significantly reduced
adhesion (14.4%; p < 0.05) towards collagen type IV.
Thus, decrease in cellular adhesion of the transfected
MDA-MB-231 cells to collagen type IV depends on the
extent of the rab31 protein level (Figure 4A). Likewise,
similar results were obtained for the ECM proteins
fibronectin, laminin and collagen type I: overexpression
of rab31 led to significantly reduced adhesive capacities of
the transfected MDA-MB-231 cells to each of the ECM
proteins being most pronounced in the rab31 high expres-
sing cell clones (Table 1). Analysis of additional individualcell clones with similar (high, medium or low) rab31
expression levels showed a comparable adhesive capacity
towards ECM proteins investigated (data not shown).
The observed reduced adhesive capacity was not
restricted to rab31 overexpressing MDA-MB-231 cells
since expression of rab31 in CAMA-1 cells reduced cell
adhesion to various ECM components in a similar man-









































Figure 5 Rab31 overexpression reduces the invasive capacity
of cells in vitro. Stably transfected MDA-MB-231 cells were seeded
into the upper compartments of Matrigel™-coated invasion
chambers. After 24 h of incubation, invaded cells were fixed, stained,
and counted. At least three independent experiments were
performed in triplicates each. Results are given in %, normalized to
the number of invaded vector-transfected cells. Whisker box plots
indicate the 25th and 75th percentile, the vertical bars indicate the
10th and 90th percentile. The median value of at least three
independent experiments is indicated by a bar within the box.
Statistically significant differences (p < 0.05) to the vector control
group are indicated by an asterisk, differences between other
groups are indicated by a line with an asterisk.
Table 1 Rab31 overexpression reduces the adhesive
capacity of human breast cancer cells in vitro
rab31 batch rab31 high rab31 medium rab31 low
Col IV 82.3+/-4.0* 72.0+/-3.1* 82.4+/-4.6* 85.6+/-5.0*
Col I 84.8+/-3.0* 70.5+/-2.7* 87.4+/-4.2* 81.6+/-5.8*
Fn 84.7+/-3.2* 71.6+/-3.0* 93.4+/-7.1* 95.8+/-4.7*
Vn 82.3+/-3.3* 63.1+/-3.3* 83.8+/-4.3* 90.2+/-4.9*
Ln 81.4+/-5.4* 67.7+/-4.4* 91.1+/-8.6* 88.2+/-11.1*
MDA-MB-231 cells were seeded on 96-well plates coated with the extracellular
matrix proteins collagen type I (Col I), collagen type IV (Col IV), fibronectin (Fn),
vitronectin (Vn) or laminin (Ln). After 2 h of cell cultivation, the number of
adherent cells was monitored by the hexosaminidase activity assay. At least 5
independent experiments were performed in triplicates each. The results are
given in % relative to the cell number of adherent vector–transfected control
cells. The mean values +/- SEM are depicted. Statistically significant differences
(p < 0.05) to the vector control group are indicated by an asterisk.
Grismayer et al. Molecular Cancer 2012, 11:62 Page 7 of 14
http://www.molecular-cancer.com/content/11/1/62showed a moderate but significant reduction of adhesion
(36.4%; p < 0.05) towards collagen type IV, compared to
vector control cells. CAMA-1 cells with high expression
of rab31 showed the strongest reduction in cell adhesion
(48.5%; p < 0.05). Yet, cells with moderate rab31 overex-
pression also displayed significantly reduced adhesion
(45.1%; p < 0.05). Even low rab31 expressing cell clones
were characterized by a still significant reduction in ad-
hesion to collagen type IV (27.3%; p < 0.05), compared to
vector control cells (Figure 4B). Cell adhesion assays
performed with the various stably transfected CAMA-1
cell lines on plates coated with collagen type I and vitro-
nectin revealed similar results (data not shown).
Characterization of the invasive potential of breast cancer
cells overexpressing rab31
Next, the invasive properties of rab31 overexpressing
MDA-MB-231 cells were investigated in a MatrigelTM
invasion assay and compared to those of vector control
cells. Batch-transfected MDA-MB-231 cells showed a
moderate but significantly reduced invasive capacity
through the extracellular matrix (25.3%; p < 0.05). Strik-
ingly, MDA-MB-231 cell clones overexpressing high or
medium rab31 protein levels displayed strongly impaired
invasion (53.1% and 58.5% reduction, respectively;
p < 0.05). On the contrary, the invasive capacity of the
rab31 low expression cell clone was comparable to that
of the vector control cells (Figure 5). Parental CAMA-1
cells do not display any invasion through MatrigelTM,
thus, we did not analyze this cell line for effects of rab31
overexpression in this cell biological assay.
Effects of rab31 overexpressing breast cancer cells on
lung metastasis in a xenograft mouse-model
In order to explore the impact of rab31 overexpression
in breast cancer cells on the capacity of these cells to
form lung metastases in vivo, batch-transfected MDA-
MB-231 cells tagged with the lacZ-gene were injectedinto the tail veins of immune-compromised female nude
CD1 nu/nu mice. Mice were sacrificed 35 days after
tumor inoculation and lungs removed for X-Gal staining.
Blue colonies (indicating metastases) were identified on
the surface of the lungs and counted. The number of
lung metastases was dramatically and significantly
reduced in mice which were inoculated with cells over-expressing rab31 (n = 7; median: 13 colonies) compared
to mice injected with vector control cells (n = 7; median:
42 colonies) (Figure 6).
Discussion
Rab proteins constitute the largest family of monomeric
small GTPases. Numerous studies have established that
Rab proteins are distributed to distinct intracellular com-
partments and regulate transport between organelles.
Mutations in Rab proteins as well as altered GTPase
expression or activity were shown to be involved in
neurologic and neurodegenerative diseases, lipid storage
disorders and cancer [24]. A growing number of Rab pro-
teins such as rab5, rab11, rab21, rab25, and rab27B have
been shown to be associated with tumor growth/behavior
and prognosis of breast cancer patients [16,25,26].
However, still few data are available on rab31 expression


























Figure 6 Overexpression of rab31 affects lung colonization and
metastatic growth of human breast cancer cells. Stably
transfected, lacZ-tagged, MDA-MB-231 cells were inoculated into
nude mice via tail vein injection. Mice received either vector control
cells (grey column, n = 7) or batch-transfected rab31 cells (green
column, n = 7). Animals were sacrificed at day 35 after injection,
lungs were collected and stained with X-Gal. Metastases were
counted in lungs of the mice. Whisker box plots indicate the 25th
and 75th percentile, the vertical bars indicate the 10th and 90th
percentile. Results are expressed as the median number of
metastases. The median value is indicated by a bar within the box.
Statistically significant differences (p < 0.05) to the vector control
group are indicated by an asterisk.
Table 2 Characteristics of MDA-MB-231 cells expressing






Lung colonization ++ -
Rab31, depending on its expression level, modulates the switch between a
more proliferative versus invasive phenotype in MDA-MB-231 breast cancer
cells.
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rab31 mRNA is overexpressed in ERα-positive breast can-
cer tissue. We recently reported that elevated rab31
mRNA expression in primary tumor tissue is associated
with poor prognosis of lymph node-negative breast cancer
patients [15].
In the present study, antibodies were raised against puri-
fied recombinant human rab31 and tested for cross reactiv-
ity with other, closely related Rab proteins, rab5 and
rab22A. Because the generated polyclonal antibodies
turned out to be highly specific for rab31, rab31 protein ex-
pression was verified in breast cancer tissue by immu-
nohistochemistry. We detected a weak to moderate
cytoplasmic staining for rab31 and, occasionally, strong
perinuclear and/or nuclear staining of cancer cells, whereas
stromal cells were less frequently stained. This cellular
staining pattern is in accordance with data published in the
human protein atlas (see www.proteinatlas.org) in normal
as well as tumor tissue. Moreover, in immunocytochem-
istry, we occasionally observed a pronounced perinuclear
staining in MDA-MB-231 cells overexpressing rab31 which
is very similar to the results of published immunocyto-
chemical studies showing in different cell types a peri-
nuclear patch of rab22B/rab31 in the trans-Golgi region
[5,7,8; Additional file 1: Figure S1].
To analyze possible cellular effects of variable rab31
protein expression, we stably transfected breast cancer cell
lines with the eukaryotic expression plasmid pRcRSVharboring the rab31 cDNA sequence. In general, data
based on unphysiologically high protein overexpression
should be interpreted with caution. However, applying
Western blot analysis and, in particular, a newly developed
sensitive ELISA for quantitation of rab31, we found that
for instance in MDA–MB-231 cells rab31 protein was
increased up to about 5-fold only in the high expressing
clones ( 2 ng/mg total protein) as compared to vector
control cells ( 0.4 ng/mg total protein). In a study by
Bao et al. [31], the physiological rab31 content in platelets
was estimated to be approximately 5 ng/mg total protein.
Thus, it can be concluded that in the present study modu-
lation of rab31 levels was within the physiologic range.
On one hand, overexpression of rab31 caused enhanced
cell growth of breast cancer cells. These effects are not
related to an increase in apoptosis in vector control cells if
compared to rab31 overexpressing cells. Interestingly,
using cell lines with a basic level of endogenous rab31
expression (MDA-MB-231), high levels of rab31 were
necessary to induce a significant increase in cell prolifera-
tion. In opposite, already moderate levels of rab31 signifi-
cantly elevated proliferation in cell lines not displaying
any detectable endogenous rab31 expression (CAMA-1
and MDA-MB-435). On the other hand, high levels of
rab31 in breast cancer cells resulted in significantly
reduced adhesion towards ECM proteins as well as
decreased invasive capacity. Likewise, the effects on cell
adhesion and invasion were dose-dependent since effects
monitored in low rab31 expressing cell clones differed
significantly from those observed in rab31 high expressing
cell clones. Comparing cell lines with differential endogen-
ous rab31 levels, again the strongest effects were detected
in breast cancer cell lines not showing any detectable en-
dogenous rab31 expression (CAMA-1 and MDA-MB-435).
In line with its reduced invasive capacity in MatrigelTM
invasion assays, we observed a significantly reduced num-
ber of lung metastases in immunologically compromised
mice injected with rab31 overexpressing MDA-MB-231
cells compared to mice injected with vector control cells.
Since development and growth of tumor metastases require
that neoplastic cells must either have the potential to shift
between proliferative and invasive phenotypes or simply
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overexpression of rab31 may lead to a proliferative rather
than an invasive phenotype in breast cancer cells (Table 2).
To verify that the observed cellular effects are not
artefacts due to overexpression of a protein per se, we
also analyzed overexpression of two rab31 mutants in
MDA–MB-231 cells: rab31-Q64L is equivalent to consti-
tutively activated GTPase-deficient mutants in other Rab
proteins [33], whereas rab31-ΔCC lacks the two C-
terminal cysteine residues obligatory for prenylation
(responsible for membrane association) and, in conse-
quence, is inactive. In fact, overexpression of rab31-
Q64L in MDA-MB-231 cells, similar to wild-type rab31
overexpression, led to significantly increased cell prolif-
eration and decreased adhesion to ECM proteins,
whereas cells overexpressing the inactive rab31-ΔCC
behaved like the vector control cells (Additional file 2:
Figure S2).
Recently, it was shown that rab31 levels are regulated
by the mRNA binding protein HuR [10]. HuR is aber-
rantly expressed in early stages of breast carcinogenesis
and high cytoplasmic expression is associated with
reduced patients' survival in breast cancer [34,35].
Through its post-transcriptional influence on specific
target mRNAs, HuR modulates cellular response to pro-
liferative, apoptotic, differentiation and other stimuli
[reviewed in 36]. By enhancing the stability of rab31
transcripts and regulation of their translation, HuR may
cause higher rab31 levels in tumor cells. In fact, when
HuR expression was silenced in epithelial 184B5Me breast
cancer cells, a significant reduction of rab31 mRNA
expression was observed [10]. Consistent with published
results for other cancer types, HuR overexpression in
MDA-MB-231 breast cancer cells (also used in the present
study) resulted in increasing cellular growth rates and
alterations in cell cycle kinetics in vitro [37]. Surprisingly,
however, HuR overexpression significantly supressed
tumor growth in vivo whereas vector control and wild-
type MDA-MB-231 cells grew similarly and resulted in
much larger tumors than those formed by HuR overex-
pressing cells. This is very similar to our observation, indi-
cating a strongly reduced metastatic capacity of rab31
overexpressing cancer cells in a xenograft mouse model
despite the fact that overexpression of rab31 leads to
increased proliferation of MDA-MB-231 cells in vitro and
high rab31 mRNA levels in (highly proliferating) primary
tumor tissue are associated with a poor prognosis in
breast cancer patients [15].
In contrast to other Rab proteins [38], the molecular
mechanism of rab31 function is still unclear, in spite of
identification of cytoskeletal participation and several
interacting proteins. Immunocytochemistry analyses
indicate that a large fraction of rab31 protein is localized
to the perinuclear region, in the TGN and in endosomes[4,7,8]. Recently, it has been demonstrated that rab31
is involved in the transport of mannose 6-phosphate
(Man-6-P) receptors (MPRs), especially of the cation-
dependent (CD-)MPR, from the TGN to endosomes [6,9].
In eukaryotic cells, MPRs are key components of the
lysosomal enzyme targeting system that bind newly
synthesized Man-6-P-containing acid hydrolases and
function as efficient cargo transporters from the TGN to
endosomal/lysosomal compartments [39,40]. The two
distinct MPRs, the 46 kDa CD-MPR and the 300 kDa
cation-independent (CI-)MPR are the sole members of
the P-type lectin family [reviewed in 41]. Although CD-
MPR and CI-MPR bind the same array of proteins, the
respective affinity of each MPR for different phosphory-
lated glycoproteins varies. This provides a biochemical
mechanism, which, in part, may explain the interaction
of the two MPRs with overlapping yet distinct subsets of
ligands in vivo [42]. The CI-MPR has been described to
bind proteins bearing the Man-6-P recognition marker
as well as the peptide hormone IGF-II and to be impli-
cated in numerous cellular processes, including cell
growth, apoptosis, and cell migration [43,44]. In addition,
CI-MPR has been shown to interact also with a number of
proteins that do not contain Man-6-P such as urokinase-
type plasminogen activator receptor (uPAR) [45-47]. The
uPAR binding epitope on CI-MPR is different from those
binding Man-6-P and IGF-II. Binding of uPAR to MPRs
seems to be specific for CI-MPR and independent of its
ligand, the serine protease uPA. CI-MPR was proposed to
be involved in the turnover of uPAR and to regulate the
cell surface concentration of uPAR by directing uPAR to
lysosomes as well as internalizing uPAR when it interacts
with uPA [45]. The detection of uPAR in endosomes
agrees well with the primary function of MPRs, which is
the transport of ligands from the TGN or cell surface to
the endosome. Interestingly, both uPA and uPAR were
upregulated in CI-MPR knockdown cells [48].
Several splice variants of human uPAR have been
described and their expression was analyzed in breast
cancer cells and tissues. One of these splice variants,
uPAR-del4/5, encodes a molecular form of uPAR which
lacks domain DII of uPAR and does not interact with its
ligand uPA [21,22]. Quantification of mRNA levels of
uPAR-del4/5 in tumor tissues revealed that higher
uPAR-del4/5 expression - similar to rab31 - is associated
with shorter disease-free survival of breast cancer
patients [15,21,49]. Since uPAR as well as rab31 mRNA
are known to be regulated by the RNA binding protein
HuR both in vitro and in vivo [10,50], the observed
elevated uPAR-del4/5 as well as rab31 expression in me-
tastasizing breast cancer may be due to increased HuR
expression in these tumors and points to a possible link
between rab31 and the uPA/uPAR system in cancer
cells. All three factors, HuR, uPAR-del4/5, and rab31,
Grismayer et al. Molecular Cancer 2012, 11:62 Page 10 of 14
http://www.molecular-cancer.com/content/11/1/62have been demonstrated to modulate cellular processes
such as proliferation, adhesion and/or invasion. Strikingly,
although high expression levels of these three factors (mea-
sured in highly proliferating primary tumor tissue) are
clearly associated with poor prognosis of breast cancer
patients, in experimental animal xenograft tumor models -
using the same breast cancer cell line MDA-MB-231 - over-
expression in each case unexpectedly leads to a seemingly
reduced tumorigenicity. Tumor progression is known to be
a multi-step process, including transitions of the malignant
phenotype of tumor cells from a predominantly prolifera-
tive to a mainly invasive phenotype as well as interactions
between tumor cell and tumor-associated stromal cells. The
results obtained with the xenograft animal models, there-
fore, may not directly mirror the malignant features of
rab31-, uPAR-del4/5- or HuR overexpressing tumors in
human breast cancer. With regard to the plasticity of tumor
cells in reliance of rab31 expression, our results, however,
demonstrate that rab31 expression is implicated in modula-
tion of tumor-relevant biological processes.
Conclusions
During tumor progression, cancer cells sequentially acquire
different malignant phenotypes: in primary tumors, cell
proliferation and angiogenesis are induced; subsequently,
the invasive capacity of the tumor cells as well as their
motility is stimulated to generate micrometastases; fi-
nally, the proliferation phenotype has to be recovered
to trigger growth of the metastatic foci. In breast cancer
cells, overexpression of the GTP-binding protein rab31
(which is involved in intracellular trafficking) leads to a
switch from an invasive to a proliferative phenotype as
indicated by increased cell proliferation, reduced adhe-
sion and invasion, and a reduced capacity to form lung
metastases.
Methods
Cell culture and cell transfection
The human breast adenocarcinoma cell lines MDA-MB-
231 and CAMA-1 (American Type Culture Collection
[ATCC], Manassas, VA) were cultured in Dulbecco’s modi-
fied Eagle medium (DMEM) (Gibco BRL, Eggstein,
Germany) supplemented with 10% (v/v) fetal calf serum
(FCS) (Gibco BRL), 10 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) (Gibco BRL), 0.55 mM L-
arginine, and 0.272 mM L-asparagine (Sigma-Aldrich,
Saint-Louis, MO). In some experiments, the human MDA-
MB-435 cell line (ATCC) was used as well. Cells were
routinely checked by polymerase chain reaction (PCR) to
be free of mycoplasma infection.
Human full-length rab31 cDNA was obtained by real-
time PCR (RT-PCR) using mRNA from human breast
cancer tissue as a template. The cDNA was directionally
subcloned into the pRcRSV plasmid using 5´-HindIIIand 3´-XbaI restriction sites, which were introduced into
the cDNA by PCR. The sequence was verified by
sequencing and was found to be identical to that of the
Genbank entry NM_006868.3.
Cells were transfected using LipofectinW (Invitrogen,
Karlsruhe, Germany). Cell transfectants were selected by
addition of 1 mg/ml G418 (Gibco BRL) to the cell cul-
ture medium (Gibco BRL). In an independent transfec-
tion experiment, cell clones with a homogenous high,
medium, or low expression of rab31 were isolated by
limited dilution.
Generation of polyclonal antibodies directed against
rab31
Recombinant rab31, harboring an N-terminal histidine
(His)6-tag, was expressed in Escherichia coli and purified
by nickel-nitrilotriacetic acid agarose affinity chromatog-
raphy (Qiagen, Hilden, Germany) under denaturing/
slightly reducing conditions as described previously [51].
The purified recombinant rab31 protein, dialyzed against
phosphate-buffered saline (PBS), pH 7.4, containing 1 mM
dithiothreitol (DTT), was used as antigen for immunization
of chickens and rabbits (Pineda Antibody Service, Berlin,
Germany). Chicken IgY antibodies were purified from egg
yolk as previously described [52]. The IgG fraction of poly-
clonal rabbit antibodies was isolated from hyperimmune
serum of rabbits by protein A affinity chromatography
(Pineda Antibody Service).
One-sided ELISA for testing the reactivity of
rab31-directed polyclonal antibodies
Purified antibodies were characterized using a ‘one-sided
ELISA’ assay in which the specific antigen or an irrele-
vant protein were coated onto the wells of polystyrene
microtiter plates as described [19]. Briefly, test antigens
diluted to 1 μg/ml in coating buffer (67 mM Na2CO3,
100 mM NaHCO3, pH 9.6) were adsorbed to the wells
of 96-well microtiter plates (Thermo Scientific, Nunc,
Rochester, NY) and incubated overnight at 4°C. Follow-
ing three washing steps with Tris-buffered saline (TBS),
pH 7.4, containing 0.05% (v/v) Tween-20 (TBS-T), plates
were blocked using blocking buffer (TBS-T containing
2% [w/v] bovine serum albumin, albumin [BSA], Sigma-
Aldrich) for 1 h at room temperature (RT). After wash-
ing, polyclonal rabbit or chicken antibodies to rab31
(diluted 1:5,000 in TBS-T containing 0.5% [w/v] BSA)
were applied to the wells for 1 h at RT. Subsequently,
incubation with a secondary horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch
Lab, West Grove, PA) or an HRP-labeled rabbit anti-
chicken IgY (Sigma-Aldrich) as detection antibodies was
carried out for 2 h at RT. Antigen binding was visualized
using 3,3’5,5’-tetramethylbenzidine (TMB) / H2O2 as sub-
strate (Thermo Scientific, Pierce, Stonehouse, UK) for
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stopped by addition of 0.5 M H2SO4. The optical density of
the resulting color was determined at 450 nm using an
automated ELISA plate reader.
Extraction of proteins from breast cancer cells for
Western blotting and ELISA
Cultured MDA-MB-231 and CAMA-1 cells were washed
with PBS, pH 7.4 (Invitrogen), and cell pellets disrupted by
two freezing and thawing cycles, followed by solubilization
of rab31 antigen in extraction buffer (20 m M Tris-HCl,
125 mM NaCl, pH 7.6, containing 1% [v/v] Triton X-100,
and the “Complete” protease inhibitor cocktail, Sigma-
Aldrich). Cell lysates were centrifuged at 13,000 x g for
10 min at 4°C and the supernatant collected. The protein
content was quantified using the Pierce Micro BCATM
protein assay reagent kit (Thermo Scientific, Pierce).
Western blot
Proteins were separated by electrophoresis on 12% (w/v)
polyacrylamide gels (SDS-PAGE), and transferred to poly-
vinylidene fluoride membranes (Millipore Corporation,
Bedford, MA) in a semi-dry transfer device (Biometra,
Göttingen, Germany). Membranes were incubated for
60 min in TBS, pH 7.4, containing 0.1% (v/v) Tween-20
(TBS-T) and 5% (w/v) dried skimmed milk, followed by
an overnight incubation with the polyclonal rab31-
directed chicken or rabbit antibodies, diluted in TBS-T
supplemented with 5% (w/v) dried skimmed milk. After
washing with TBS-T, binding of the antibodies was visua-
lized by incubation of the membranes with a secondary
HRP-conjugated goat anti-rabbit IgG (Jackson ImmunoR-
esearch Lab) or an HRP-labeled rabbit anti-chicken IgY
(Sigma-Aldrich), followed by chemiluminescent reaction
using ECL (Thermo Scientific, Pierce).
ELISA for quantitative assessment of rab31
For detection of rab31 in cell lysates, a sandwich ELISA
format was developed using a commercial monoclonal
antibody (mAb) to rab31 (mAb M01, Novus Biologicals,
Inc., Littleton, CO) as catcher antibody and own poly-
clonal antibody (pAb) from rabbit #3 (RT3-IgG) as detect-
ing antibody. Recombinant, purified rab31-His protein,
dialyzed against PBS, pH 7.4, containing 1 mM DTT, was
used as the reference antigen (stock 20 μg/ml). Ninety-
six-well polystyrene plates (MaxiSorpTM; Thermo Scien-
tific, Nunc) were coated overnight at 4°C with mAb M01
(clone 1C6; Novus Biologicals) diluted in coating buffer
(15 mM Na2CO3, 33 mM NaHCO3, pH 9.6). After wash-
ing of the plates twice with washing buffer (PBS, contain-
ing 0.5% [v/v] Tween 20, pH 7.6), wells were blocked with
blocking solution (washing buffer containing 2% [v/v]
neonatal calf serum; Gibco BRL) for 30 min at 37°C.
Thereafter, plates were incubated with cell lysates dilutedin sample buffer (50 mM Tris-HCl, 100 mM NaCl, con-
taining 0.2% [v/v] Triton X-100, and 0.2% [w/v] BSA, pH
7.6) for 90 min at 37°C. Two-fold serial dilutions of
recombinant rab31-His protein in sample buffer, covering
a concentration range of 0.15 to 5 ng/ml, were employed
to construct a standard curve. After washing, wells were
incubated with pAb RT3-IgG for 90 min at 37°C followed
by incubation with secondary HRP-labeled goat anti-
rabbit IgG (Novus Biologicals) for 60 min at 37°C. Finally,
plates were washed and the peroxidase reaction initiated by
addition of TMB/H2O2 (K & P Laboratories, Gaithersburg,
MD) as the peroxidase substrate. After 20 min at RT,
the reaction was stopped by addition of 0.5 M H2SO4.
The optical density of the resulting color was deter-
mined at 450 nm (reference wavelength 620 nm) using
an automated multichannel ELISA reader. Rab31 anti-
gen levels are given as ng per mg of total protein.
Immunohistochemistry
Full-face sections from invasive ductal breast cancer
tissue specimens were selected for immunostaining with
pAb RT3-IgG and pAb from animal #4 (RT4-IgG),
respectively. Formalin-fixed, paraffin-embedded breast
cancer tissue specimens were obtained from archival
material of the Institute of Pathology, Dresden University
of Technology. The study adhered to national regulations
on ethical issues and was approved by the local ethics
committee at the Dresden University Medical Center.
Immunohistochemical staining was performed as described
previously with minor modifications [19,53]. Briefly, tissue
sections were dewaxed, rehydrated, and treated for antigen
retrieval by pressure cooking (15 min at 120°C) in 100 mM
citrate buffer, pH 6.0. After several washes with PBS, sec-
tions were treated with 0.3% H2O2 for 10 min at RT to
block endogenous peroxidase activity. Normal serum
diluted in PBS was applied for 45 min at RT to block
nonspecific antibody binding. Subsequently, primary anti-
bodies (dilution: 1:2,000) were allowed to react over-
night at 4°C followed by incubation with biotinylated
anti-rabbit IgG (Vectastain Elite ABC Kit, Vector
Laboratories, Burlingame, CA) for 50 min at RT. After
washing, the Vectastain Elite ABC-reagent was applied for
50 min at RT, and the washing steps were repeated. The per-
oxidase reaction was developed with 3,3’-diaminobenzidine
(Sigma-Aldrich) for 10 min at RT. Finally, counterstain-
ing of nuclei was performed with hematoxylin. As a
negative control, the primary antibody was omitted and
replaced by PBS or by an irrelevant antibody.
Cell-based in vitro assays
Proliferation assays
Transfected MDA-MB-231 (and MDA-MB-435) cells
were seeded in 24-well microtiter plates at a density of
20,000 cells per well, CAMA-1 cells at a density of 30,000
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or 96 h at 37°C. After incubation, cells were detached by
PBS plus 0.05% (w/v) EDTA (Biochrom AG, Berlin,
Germany). Living cells were identified by trypan blue
exclusion and counted in a hemocytometer under a
light microscope.
Cell adhesion assays
Ninety-six-well plates were coated for 1 h at RT with
vitronectin (2 μg/ml) or fibronectin (5 μg/ml) (BD Bios-
ciences, Franklin Lakes, NJ), or for 3 h at 37°C with
5 μg/well of laminin, collagen type I or collagen type IV
(Sigma-Aldrich), all diluted in PBS. Cells were resus-
pended in culture medium containing 0.5% (w/v) BSA
and HEPES (Invitrogen), were seeded at a density of
20,000 cells/well (MDA-MB-231 and MDA-MB-435) or
30,000 cells/well (CAMA-1), and allowed to adhere to
the extracellular matrix proteins for 2 h at 37°C. Subse-
quently, non-adherent cells were removed by washing
three times with PBS. The number of adherent cells was
quantified by a hexosaminidase activity assay. For this,
cells were incubated with p-nitrophenyl-N-acetyl-β-D-
glucosaminide (Sigma-Aldrich) diluted to 15 mM in
100 mM sodium citrate, pH 5.0, containing 0.5% (v/v)
Triton X-100 for 90 min at 37°C. The reaction was ter-
minated by the addition of stop buffer (0.2 M NaOH,
5 mM EDTA) and the optical density recorded at
405 nm using an automated ELISA reader.
Cell invasion assays
Invasion assays were performed using transwell inserts
(8 μm pore size; Corning Costar, Amsterdam, The
Netherlands). Thirty μg of basement membrane complex
growth factor reduced MatrigelTM (BD Biosciences) was
diluted in 100 μl cold FCS-free DMEM, containing 0.1%
(w/v) BSA and applied to the upper side of the insert.
After 3 h incubation at 37°C, followed by overnight incu-
bation in a laminar hood at RT, inserts were rehydrated
with 200 μl FCS-free DMEM, containing 0.1% (w/v) BSA
for 2 h at 37°C. Cells suspended in culture medium were
seeded into the upper chamber of the device at a density
of 40,000 cells/chamber. The lower chambers were filled
with 600 μl DMEM supplemented with 10% (v/v) FCS as
the chemoattractant. After 24 h incubation at 37°C, Matri-
gelTM and non-invaded cells, located on the upper side of
the insert, were removed with a Q-tip, whereas invaded
cells on the lower side of the insert were fixed, stained
using Hemacolor (Merck, Darmstadt, Germany), and
counted under a light microscope.
Experimental metastasis assay
MDA-MB-231 cells are tumorigenic and invasive cells,
which upon intravenous injection in mice colonize to
the lungs [54]. Transfected MDA-MB-231 cells weregenetically tagged with the lacZ-gene, allowing X-Gal
staining, as reported previously [55]. Pathogen-free, 8 to
10 weeks old female athymic (nu/nu) mice were obtained
from Charles River Laboratories (Sulzfeld, Germany).
Mice were allocated to two groups and 1× 106 control
MDA-MB-231-vector cells (n= 7) or pRcRSV-rab31-
transfected MDA-MB-231 (batch) cells (n= 7) intraven-
ously inoculated into the tail vein. At day 35 post-injection
animals were sacrificed, lungs isolated and the lacZ-tagged
tumor cells stained with 5-bromo-4-chloro-indolyl-β-
D-galactopyranoside (X-Gal) (Roche Diagnostics,
Mannheim, Germany) as described [56]. Thereafter,
blue stained cellular foci were counted as metastases.
All animal experiments were done in compliance with
the guidelines and with confirmed ethical approval of
the Tierschutzgesetz des Landes Bayern (Regierung von
Oberbayern).
Statistical analyses
Group differences and p-values were calculated using the
Mann-Whitney U-test. P values < 0.05 were considered as
statistically significant.
Additional files
Additional file 1: Figure S1. Analysis of MDA-MB-231 cell transfectants
for rab31 expression by immunofluorescence. After overnight growth on
fibronectin-coated glass slides, the cell monolayers were fixed and
permeabilized with PBS containing 4% (w/v) paraformaldehyde, 0.025%
(w/v) saponin. After incubation, the rabbit antibody directed to rab31
was detected with Alexa488-labeled goat anti-rabbit IgG (Sigma-Aldrich)
and fluorescence signal intensity visualized by confocal laser scanning
microscopy (CLSM). Typical fluorescent images (lower panel) together
with the corresponding differential interference contrast images (upper
panel) are depicted. In immunocytochemistry, a often pronounced
perinuclear staining is visible. There are no apparent morphological
differences between vector control cells and cells overexpressing rab31.
Additional file 2: Figure S2. The constitutively active rab31-mutant
Q64L, but not the inactive form rab31-ΔCC, induces cell growth and
reduces cell adhesion, when overexpressed in MDA-MB-231 breast cancer
cells. (A) Overexpression of rab31 mutants in breast cancer cells.
MDA-MB-231 cells were stably transfected with rab31 expression
plasmids encoding either the constitutively active mutant Q64L, the
inactive form rab31-ΔCC, or the empty vector pRcRSV only. Western blot
analysis demonstrated low endogenous rab31 expression in vector
control cells, whereas the cells overexpressing either of the rab31
mutants display strongly elevated, but similar rab31-reactive protein
levels. (B) Overexpression of rab31-Q64L, but not rab31-ΔCC,
enhances cell growth of breast cancer cells. Stably transfected MDA-
MB-231 cells were seeded in triplicate onto 24-well plates, detached with
0.1% EDTA-solution after 24 and 96 h of cultivation and counted with a
Neubauer hemocytometer under trypan blue exclusion. Cell number at
24 h was set to 100%; increase in cell number was expressed relative to
the 24 h value in %. Mean values (± SEM) of seven independent
experiments are depicted. Statistically significant differences (p≤ 0.01) are
indicated by an asterisk. (C) Overexpression of rab31-Q64L, but not
rab31-ΔCC, reduces the adhesive capacity of breast cancer cells.
Stably transfected MDA-MB-231 cells were seeded on collagen type IV-
coated 96-well plates. After 2 h of cell cultivation, the number of
adherent cells was monitored by the hexosaminidase activity assay as
described in the Methods section. Seven independent experiments were
performed in triplicates each. The results are given in % relative to the
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plots indicate the 25th and 75th percentile, the vertical bars indicate the
10th and 90th percentile. The median value of seven experiments is
indicated by a bar within the box. Statistically significant differences
(p < 0.01) are indicated by an asterisk. Similar effects were observed with
the extracellular matrix proteins collagen type I, laminin, vitronectin, and
fibronectin (data not shown).
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